Jakob Jensen, PhD, professor in the Department of Communication at the University of Utah and member of the Huntsman Cancer Institute, discusses rural residents’ beliefs and perceptions of cancer-related information in comparison with those of urban residents.
Thomasina Morris, RPh, MHA, BCOP, pharmacist at Moffitt Cancer Center, discusses the efficacy of rucaparib for approved indications based on clinical trial results.
A supplemental application was also submitted for an oral suspension formulation to provide an alternative administration option for children.
Pacritinib becomes the first treatment approved to specifically address the needs of patients with cytopenic myelofibrosis.
Majority of heavily pretreated patients with multiple myeloma administered ciltacabtagene autoleucel (cilta-cel; Carvykti) achieved deep responses after 18-months follow-up.
Thomasina Morris, RPh, MHA, BCOP, pharmacist at Moffitt Cancer Center, discusses how rucaparib is currently used when treating patients with ovarian cancer.
Results of studies show that women with obesity who get these weight loss procedures often also have preventative benefits.
Thomasina Morris, RPh, MHA, BCOP, pharmacist at Moffitt Cancer Center, discusses the mechanism of action of rucaparib in recurrent and second line ovarian cancer, fallopian tube cancer, and peritoneal cancer.
Combination netupitant and palonosetron capsules/fosnetupitant and palonosetron for injection (Akynzeo) is indicated to prevent acute and delayed nausea and vomiting associated with highly emetogenic chemotherapy.
Steven Sims, MD, discussed his upcoming research into how transnasal esophagoscopy could help address disparities in esophageal cancer diagnoses.
Trastuzumab deruxtecan demonstrated clinically meaningful and statistically significant improvements in overall and progression-free survival, the company says.
Ten quiz questions to assess your knowledge on common symptoms and treatments for Hodgkin's lymphoma.
Women who get these screenings starting at aged 30 to 35 years could cut their cancer mortality by more than 50%, new study results show.
The drug combination reduced the risk of disease progression by 34% versus the standard of care in first-line metastatic castration-resistant prostate cancer, clinical trial results show.
Cohort H of the phase 1b/2 EV-103 trial enrolled patients with MIBC who were eligible for surgical treatment but ineligible for cisplatin-based chemotherapy.
Dalpiciclib added to fulvestrant (Faslodex) was found to significantly prolong progression-free survival compared with fulvestrant monotherapy in patients with hormone receptor–positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
Just 2 of 41 nutritionists interviewed reported using a validated screener, while 4 others said they use other tools, such as screening questions developed by other organizations, results show.
FDA to evaluate adagrasib for the treatment of patients with non–small cell lung cancer with tumors that have a KRAS G12C mutation.
Results of CheckMate-9ER trial in first-line advanced renal cell carcinoma will be featured in 2 poster presentations at the American Society of Clinical Oncology 2022 Genitourinary Cancers Symposium.
The common-weight loss plan synergizes with chemotherapy to triple survival time compared with the treatment alone in rigorous mouse models of PDAC, the analysis shows.
The drug pipeline is insufficient to meet the threat of antimicrobial resistance, and policy reforms are critically needed, according to the Biotechnology Innovation Organization.
All the participants were in the Beating Lung Cancer in Ohio study, which started before the COVID-19 pandemic.
Niraparib is associated with increased progression-free survival, regardless of the presence or absence of BRCA gene mutations.
The use of these services in oncology is likely here to stay.
The drug's novel molecular structure may result in fewer toxic adverse effects.
A variety of drugs from several medication classes are under investigation.
Study shows that treatment with rituximab (Rituxan) for B-cell non-Hodgkin lymphoma prior to COVID-19 vaccination significantly lowered the number of patients who developed blocking antibodies for the virus.
An emerging focus is aligning targeted, safe, and effective therapies with patient goals.
Ixazomib (Ninlaro, Takeda) has been found to improve survival in patients with multiple myeloma who have not undergone autologous stem cell transplant.
Larotrectinib was the first drug to receive accelerated FDA approval for patients of all ages based on a common molecular marker, independent of tissue origin for targeted therapy.
